Your browser doesn't support javascript.
loading
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
Maria Noel Badano; Florencia Sabbione; Irene Keitelman; Matias Javier Pereson; Natalia Aloisi; Ana Colado; Victoria Ramos; Juan Manuel Ortiz Wilczynski; Roberto Pozner; Luis Castillo; Georgina Wigdorovitz; Maria M E de Bracco; Susana Fink; Roberto Chuit; Patricia Bare.
Afiliación
  • Maria Noel Badano; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
  • Florencia Sabbione; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
  • Irene Keitelman; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina. Postal address: J
  • Matias Javier Pereson; Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Instituto de Investigaciones en Bacteriologia y Virologia Molecular (IBaViM). Buenos Aires, Arge
  • Natalia Aloisi; Instituto de Investigaciones Hematologicas (IIHEMA), Academia Nacional de Medicina
  • Ana Colado; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina.
  • Victoria Ramos; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina.
  • Juan Manuel Ortiz Wilczynski; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
  • Roberto Pozner; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
  • Luis Castillo; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
  • Georgina Wigdorovitz; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina. Postal address: J
  • Maria M E de Bracco; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina. Postal address: J
  • Susana Fink; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina. Postal address: J
  • Roberto Chuit; Instituto de Investigaciones Epidemiologicas (IIE), Academia Nacional de Medicina
  • Patricia Bare; Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Academia Nacional de Medicina
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21264432
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina. Seroconversion rates in unexposed subjects after the first and second doses were 40% and 100%, respectively, showing a significant increase in antibody concentrations from dose 1 to dose 2 (p<0.0001). The highest antibody concentrations were found in younger subjects and women, remaining significantly associated in a multivariable linear regression model (p=0.005). A single dose of the BBIBP-CorV vaccine induced a strong antibody response in individuals with prior SARS-CoV-2infection, while a second dose did not increase this response. A sharp increase in antibody concentrations was observed following SARS-CoV-2 infection in those participants who became infected after the first and second doses (p=0.008). Individuals with SARS-CoV-2 exposure prior to vaccination showed significantly higher anti-spike IgG antibody levels, at all-time points, than those not exposed (p<0.001). Higher antibody titers were induced by a single dose in previously SARS-CoV-2 infected individuals than those induced in naive subjects by two doses of the vaccine (p<0.0001). Three months after the second dose both groups showed a decline in antibody levels, being more abrupt in unexposed subjects. Overall, our results showed a trend towards lower antibody concentrations over time following BBIBP-CorV vaccination. Sex and age seem to influence the magnitude of the humoral response in unexposed subjects while the combination of exposure to SARS-CoV-2 plus vaccination, whatever the sequence of the events was, produced a sharp increase in antibody levels. Evaluation of the humoral responses over time and the analysis of the induction and persistence of memory B and T cell responses, are needed to assess long-term immune protection induced by BBIBP-CorV vaccine.
Licencia
cc_by_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint